Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK - Wikidata - awgldk - TriplyDB

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

http://www.wikidata.org/entity/Q35156866

about

Role of the tumor microenvironment in mature B-cell lymphoid malignancies Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)Immune checkpoint inhibitors: therapeutic advances in melanoma PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)Myeloid Cells as Targets for Therapy in Solid Tumors Advances in Cancer Immunotherapy in Solid Tumors Targets for Ibrutinib Beyond B Cell Malignancies A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival.Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis.A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia The Basis of Oncoimmunology Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas.Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.New Pharmacotherapies in Chronic Lymphocytic Leukemia.The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression.B-cell receptor pathway modulators in NHL.Immunologic approaches for the treatment of multiple myeloma.Immune checkpoint blockade in lymphoid malignancies.Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant.PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future.Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.The emerging role of immune checkpoint inhibition in malignant lymphoma.Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.1,2,3,-Triazole-Based Catalysts: From Metal- to Supramolecular Organic Catalysis.PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.Ibrutinib as an antitumor immunomodulator in patients with refractory chronic lymphocytic leukemia.Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders.The landscape of new drugs in lymphoma

P2860

Q26748775-C4FCFBD6-B13A-4109-9D6E-0671D1979C96 Q26768154-01BF1C74-F3F2-4C89-95B9-C2B27D3CBF12 Q26775591-E28230F8-4F76-4308-B239-8D22E80D3A09 Q26782633-E04A66C6-7017-448D-8961-8CE6DAEA7A0A Q26801832-544F681C-C840-42CC-82C8-FD1FF0EA80A9 Q28080113-A09CBA7A-490B-40B6-83F7-18A1446F7BCA Q28087772-FEAFABD0-CD98-469A-A896-135AF4B1409B Q30239781-3084857D-1549-42C1-8D13-3079B8C43679 Q33591876-4EBEFE3F-219B-405B-9240-B577F1A6073F Q35220644-AB5B94C4-8320-445E-9336-4493B14EA00F Q36030084-B0744A74-52EB-4ABE-A8BD-FE77AEC311C0 Q36413780-958833D5-A8C8-48F1-8B3E-73C54A6C874E Q36522770-9D5C14DE-7A08-4FED-8D8C-51BF07FCB518 Q36535465-55E17C2A-0CC2-40FD-A7EC-731B82688F4C Q36651344-17AA511A-E40E-4424-9E50-C89B57D81B82 Q36678851-2FFAA987-7D1B-4AB2-BC50-A6FDE3486863 Q36759082-8FD83C6C-2CFE-40AB-BC36-C8BE19EA3B81 Q36759124-99433178-530C-4626-B545-81F6C8B32939 Q36918248-57524DCD-0A39-44E4-A92A-AC4FBBAFB178 Q37085973-72F7D044-A187-427D-8822-93DA3C51EFEC Q37528067-6057F779-6F26-46D9-B022-D2E8DD116A98 Q37593573-999D09F1-ED17-49B0-8523-9C80780DA870 Q37605306-E98A7283-10AD-4442-9334-E5D8CAF0ED5E Q37695311-1B9B21EB-64C8-4E00-A479-6D0B4F71B9F8 Q38659428-85B2F6E5-907B-4C78-A061-E948FDE3B9D3 Q38692244-B2394FC0-7536-47CB-824F-8AE354F64231 Q38710672-BB0C2F51-8973-4ACF-9915-50F36E27B550 Q38765458-104DBB4E-6E6D-48DA-9165-7CA5CB712680 Q38765760-BFB5CD08-6EFC-4746-A924-16D67C21494D Q38766891-371E630D-803E-401A-B3D1-10DFA40DB2D2 Q38791036-73AC3557-E40B-427C-B674-09480C9CA599 Q38808099-286D6F4F-5989-4A04-9BE2-C7E7EB05462A Q38818283-BCCE028A-1E40-48AF-9413-A1C8D4E2BA44 Q38821875-E87E57D8-BDD1-4657-8B69-7E0B34F26859 Q38837680-5B044F38-48EC-4A15-85D4-B3E632297B5A Q38989386-29C37F3A-8507-4436-A083-8A317CBC4BC1 Q38996724-4AD38142-642B-49D2-B4B2-30687218DF4F Q38998430-03F9D0CF-5DF1-484B-BF7F-A86BD963DE4E Q39055861-DF6BF581-9983-4E0E-B476-0012D9377FF0 Q39061630-701DAAEA-0FDC-49AD-BD6D-ACF7457FC761

P2860

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

http://www.wikidata.org/entity/Q35156866

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Therapeutic antitumor immunity ...... inhibitor of both BTK and ITK

@ast

Therapeutic antitumor immunity ...... inhibitor of both BTK and ITK

@en

type

label

Therapeutic antitumor immunity ...... inhibitor of both BTK and ITK

@ast

Therapeutic antitumor immunity ...... inhibitor of both BTK and ITK

@en

prefLabel

Therapeutic antitumor immunity ...... inhibitor of both BTK and ITK

@ast

Therapeutic antitumor immunity ...... inhibitor of both BTK and ITK

@en

P1433

Q35156866-B369A2F9-CCA6-4F39-B2B1-E8A6B562132F

P1476

Q35156866-1EC10A77-63D2-4835-803F-BEF7079E7C39

P2093

Q35156866-38B9D37E-0674-42B9-9DA1-6814723EEDE7

Q35156866-6237C241-629E-45A9-B208-E8CE62A13F4D

Q35156866-798088DC-A062-4E69-AF91-113636BD49A3

Q35156866-96826984-706A-46F8-9D4D-D7D196705F4D

Q35156866-BF473F3D-B3FE-4385-9496-9D865C37C221

Q35156866-FE9DF7EF-0946-4E07-967C-5A00102A195D

P2860

Q35156866-0CA8469E-344F-4796-A750-67EA046F92FF

Q35156866-107FA9B7-B38C-4653-9C90-677A90F37FC5

Q35156866-24651D55-7F1B-43B5-A5A6-D6102C7E7619

Q35156866-2957EE09-26F1-408E-AAF9-FE9F2FA485A9

Q35156866-3C2ACF0E-D098-4FEE-A8EA-969618E53D8D

Q35156866-452262CC-4380-41AB-BDF1-1D2E76B9E386

Q35156866-53535BE0-ECB1-483C-BF48-027041DEB5C4

Q35156866-5D4ADB9E-AD14-4373-8C92-715A71D0A2E3

Q35156866-6A75F7E4-892D-4ECA-AA3B-C5E0B7262496

Q35156866-73565FA6-0FFC-4F5A-9743-4748167AA551

P304

Q35156866-4CCA0C7B-2887-452E-A3DB-783A792189DC

P31

Q35156866-0D237E2B-0670-4924-8EAA-CA2BEB05F75F

P356

Q35156866-BD8994CC-629B-4D1A-81A2-61F54EE82A74

P407

Q35156866-5A80FA9C-4B26-4F07-BA36-8FC4C2D0994B

P433

Q35156866-AB44BA7A-46B4-401A-ABA6-8E75288A9EC4

P478

Q35156866-9BE00D45-0859-426D-81D5-311D4A8A3887

P577

Q35156866-427CDD76-BA90-4441-94EA-E7C0FB103043

P5875

Q35156866-8D52C8DD-4558-4D68-9E48-2F890119481A

P698

Q35156866-BB398564-AEAA-4179-ACC2-9D6AD79551C1

P932

Q35156866-72FADA4E-C59E-4862-B8C9-CAF2B8DCC4D9

P356

PNAS.1500712112

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Therapeutic antitumor immunity ...... inhibitor of both BTK and ITK

@en

P2093

Betty Y Chang

http://www.w3.org/2001/XMLSchema#string

Debra K Czerwinski

http://www.w3.org/2001/XMLSchema#string

Holbrook E K Kohrt

http://www.w3.org/2001/XMLSchema#string

Idit Sagiv-Barfi

http://www.w3.org/2001/XMLSchema#string

Patrick P Ng

http://www.w3.org/2001/XMLSchema#string

Ronald Levy

http://www.w3.org/2001/XMLSchema#string

P2860

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Nivolumab plus ipilimumab in advanced melanoma.

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

PD-1 and its ligands in tolerance and immunity

Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer

Hepatotoxicity with combination of vemurafenib and ipilimumab

Subsets of myeloid-derived suppressor cells in tumor-bearing mice

P304

E966-72

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1500712112

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273064654

http://www.w3.org/2001/XMLSchema#string

P698

25730880

http://www.w3.org/2001/XMLSchema#string

P932

4352777

http://www.w3.org/2001/XMLSchema#string